a. Epidemiology SLR
Category Inclusion Criteria Exclusion Criteria
Patient Population
  • Adult patients (age ≥18) with IgAN regardless of comorbidities*
  • Non-human
  • Pediatric patients (age <18) only
  • Patients with other diseases
Intervention
  • Any treatment or management
  • No treatment or management
  • Any non-IgAN treatment or management
Outcomes Measures
  • Incidence, prevalence, rate of IgAN
  • Progression rate of IgAN through CKD stage and to ESRD
  • Patient distribution across CKD stage
  • Treatment rate
  • Mortality
  • Studies that did not have ≥1 outcome in the inclusion criteria
Study Design
  • RWE studies including:
    • Prospective observational studies
    • Retrospective studies
    • Registry analyses
    • Database analyses
    • Natural history studies and non-interventional studies
  • SLRs and meta-analyses (for cross-checking only)
  • Reviews
  • Editorials
  • Notes/comments/letters
  • Interventional studies
  • Studies with <20 patients in the whole population
  • Case reports/case series
Restrictions
  • English language
  • Studies in the United States, Western Europe, or Australia
  • Year limitation: 2010 to June 2020
  • Non-English language studies
  • Studies outside of United States, Western Europe, or Australia

* Studies with mixed populations of adults and children were included

Abbreviations: BOI, burden of illness; CKD, chronic kidney disease; ESRD, end-stage renal disease; IgAN, immunoglobulin A nephropathy; PICOS, Population, Intervention, Comparators, Outcomes, and Study Design; RWE, real-world evidence; SLR, systematic literature review.
b. BOI SLR
Category Inclusion Criteria Exclusion Criteria
Patient Population
  • Patients with IgAN regardless of comorbidities
  • Non-human
  • Patients with other diseases
Intervention
  • Any treatment or management
  • No treatment or management
  • Any non-IgAN treatment or management
Outcomes Measures
  • HRQoL outcomes
  • PROs
  • Utilities
  • Symptom burden
  • Costs (direct and indirect)/HCRU
  • BOI
  • Other QoL or economic burden
  • Studies that did not have ≥1 outcome in the inclusion criteria
Study Design
  • RWE studies including:
    • Prospective observational studies
    • Retrospective studies
    • Registry analyses
    • Database analyses
    • Natural history studies and non-interventional studies
  • SLRs and meta-analyses (for cross-checking only)
  • Reviews
  • Editorials
  • Notes/comments/letters
  • Interventional studies
  • Case reports/case series
Restrictions
  • English language
  • Year limitation: 2010 to June 2020
  • Non-English language studies

Abbreviations: BOI, burden of illness; HCRU, health-care resource utilization; HRQoL, health-related quality of life; IgAN, immunoglobulin A nephropathy; PRO, patient-reported outcome; QoL, quality of life; RWE, real-world evidence; SLR, systematic literature review.